Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3330067 | Critical Reviews in Oncology/Hematology | 2008 | 11 Pages |
Abstract
For most tumors, RT can provide sustained local control. However, HCC tends to recur within the liver away from the irradiated volume, providing rationale for combining RT with systemic or regional therapies. There is a particular interest in combining RT with anti-VEGF-targeted agents for their independent activity in HCC as well as their radiation sensitization properties. Randomized trials of RT are warranted.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
R.V. Tse, Chandan Guha, L.A. Dawson,